# Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

> **NCT01568021** · — · COMPLETED · sponsor: **Allergan** · enrollment: 100 (actual)

## Conditions studied

- Retinal Vein Occlusion
- Macular Edema

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT01568021
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568021, "Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT01568021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*